Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q2 EPS of $4.05, $0.48 better than the analyst estimate of $3.57. Revenue for the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE